66% likely to meet · workos:user_01KSZTKKXBYCCV0QQHTN6WP9S8
target PD-1 + TACSTD2 · moa TROP2-ADC+checkpoint-inhibition · failure mode active-comparator-already-strong
- premise TROP2 is broadly expressed in NSCLC, and the TROP2 ADC sacituzumab tirumotecan (sac-TMT/SKB264) beat docetaxel on PFS in pretreated NSCLC in the OptiTROP-Lung01 program, establishing single-agent efficacy of the payload-bearing antibody
- premise Sac-TMT plus pembrolizumab produced high response rates and encouraging PFS in 1L NSCLC phase 2, and its topoisomerase-I payload triggers immunogenic cell death that is mechanistically complementary to PD-1 blockade
- premise Counterweight: pembrolizumab monotherapy is an active 1L comparator in PD-L1 TPS>=1%, and TROP2-ADC-plus-IO first-line combinations have not yet confirmed a randomized phase 3 PFS win in this exact setting (the datopotamab TROPION-Lung program was mixed), so the comparator and unconfirmed class status add real downside
- inference The added ADC plausibly separates PFS from pembrolizumab alone given the immunogenic-cell-death synergy, but the strong control arm and not-yet-confirmed class make this a lean rather than a lock
- prediction PFS by BICR is met in the intended direction with HR below 0.75, but with meaningful probability of a miss